Overview:
The global market for neurosyphilis can be studied on the basis of a detailed report conducted by Market Research Future (MRFR). As per the report, the market is on a course to surpass a valuation of USD 957.4 million by 2023. The market is relying on several factors like rapidly developing the pharmaceutical sector, a better understanding of various market forecasts, and the inclusion of various new technologies in the pipeline, various government initiatives, and others. Better technological scope and expansion possibilities in various emerging countries are expected to boost the global market stand. The forecast period from 2017 to 2023 would see the neurosyphilis market garner a CAGR of 3.9%.
Segmentation:
The global report on the neurosyphilis market can be segmented for a detailed study by type, diagnosis, treatments, and end user. This segmentation allows a closer look at various market dynamics and factors that may help the market in its evolution in the coming years.
By type, the analysis of the neurosyphilis market includes meningeal neurosyphilis, general paresis, tabes dorsalis, meningovascular neurosyphilis, asymptomatic neurosyphilis, and others.
By diagnosis, the neurosyphilis market study spans across spinal tap, imaging tests, blood tests, physical exams, and others. The blood test segment can be sub-segmented into Fluorescent treponemal antibody absorption (FTA-ABS), Venereal disease research laboratory (VDRL) test, Treponema pallidum particle agglutination assay (TPPA), Rapid plasma reagin (RPR), and others. The imaging tests segment includes studies on X-rays, Magnetic resonance imaging (MRI), Computed Tomography (CT), and others.
By treatments, the segmentation of the market includes antibiotics probenecid, ceftriaxone, antibiotic penicillin, and others. The study of the antibiotic penicillin includes Injection and oral.
By end user, the global study of the market includes several medical research centers, academic institutes, hospital and clinics, and others.
Regional Analysis:
The North American market is in a good position to lead the market as their infrastructural superiority would boost their prospect. Infrastructure is just one aspect among many. Others are constant influx of funding, better investment in the research and development sector, the high impact from new entrants in the market with latest innovations, and others. In Europe, the market would gain from the increasing acknowledgment of the disease and various development in treatments. In Asia Pacific, this growth would be bolstered by developing countries like South Korea, India, and China, where the structural change in the healthcare sector would propel the market ahead. Japan would contribute significantly.
Competitive Landscape:
The global market for neurosyphilis is expected to benefit from the strategic moves of various market players. These companies are Bayer AG (Germany), Abbott (US), GlaxoSmithKline plc. (UK), Sanofi (France), Eli Lilly and Company (US), Pfizer Inc. (US), Novartis AG (Switzerland), and others. The market would get substantial backing from several tactical moves of these companies that would include mergers, acquisitions, joint ventures, hike in various types of funding including research and development, innovations and diverse product launching strategies, marketing innovations, expansion plans, and others are expected to provide substantial growth prospect to the market. In MRFR’s report, the company profiling process included these factors owing to which the neurosyphilis market may find growth to be substantial.
Industry News:
In March 2020, a blend of high sensitivity treponemal and enriched specificity nontreponemal results can now provide a higher chance of neurosyphilis diagnosis with an increased level of accuracy. This Dual Path Platform (DPP®) assay (Chembio, Medford, NY) is a point-of-care (POC) method that does not require a high-level of expertise owing to which it can be used by non-professionals as well. This is surely going to boost the market prospect of the product.

https://www.marketresearchfuture.com/reports/neurosyphilis-market-4021